| 06th week of 2014 patent applcation highlights part 43 |
| Patent application number | Title | Published |
|---|
| 20140037596 | Use of Stem Cells to Reduce Leukocyte Extravasation - The invention is generally directed to reducing inflammation by means of cells that secrete factors that reduce leukocyte extravasation. Specifically, the invention is directed to methods using cells that secrete factors that downregulate the expression of cellular adhesion molecules in vascular endothelial cells. Downregulating expression of cellular adhesion molecules reduces leukocyte adhesion to the endothelial cells such that extravasation is reduced. The end result is a reduction of inflammation. The cells are non-embryonic non-germ cells that have pluripotent characteristics. These may include expression of pluripotential markers and broad differentiation potential. | 2014-02-06 |
| 20140037597 | Sulfated Depolymerized Derivatives of Exopolysaccharides (EPS) From Mesophilic Marine Bacteria, Method For Preparing Same, And Uses Thereof In Tissue Regeneration - The invention relates to certain low-molecular weight sulphated polysaccharide derivatives of marine native exopolysaccharides (EPSs) excreted by mesophilic marine bacteria from a deep hydrothermal environment, wherein said derivatives can be obtained by means of a method which comprises a step of free radical depolymerisation of said native EPSs followed by a step of sulphating the resulting depolymerised derivatives. The present invention further relates to the use of said low-molecular weight sulphated polysaccharide derivatives as a wound-healing agent, particularly for preparing pharmaceutical compositions suitable for treating or preventing diseases of the connective tissues and particularly skin and gum tissues. The figure demonstrates how polysaccharide derivative GY 785 DRS according to the invention can stimulate fibroblast proliferation in latticed or reconstructed connective tissues at a concentration of 10 μg (m) g/ml. | 2014-02-06 |
| 20140037598 | THERAPEUTIC PRODUCTS COMPRISING VITALIZED PLACENTAL DISPERSIONS - This invention provides a fluid therapeutic placental product comprising placental cells and a placental dispersion comprising placental factors. The placental cells and the placental dispersion are derived from placental tissue. A placental tissue can optionally be an amnion, chorion, or a trophoblast-depleted chorion. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment. | 2014-02-06 |
| 20140037599 | Compositions and Methods of Treating T Cell Deficiency - The invention provides compositions and methods for genetically modifying T cell progenitor cells (TCPC) to express TCF-1 to differentiate the TCPC, or its progeny, into a T cell. The invention also provides methods of using a T cell derived from a TCPC to treat a subject having a disease or disorder involving T cell deficiency. | 2014-02-06 |
| 20140037600 | HEMATOPOIETIC PRECURSOR CELL PRODUCTION BY PROGRAMMING - The invention generally regards methods for providing ematopoietic cells and precursors of hematopoietic cells from a variety of cell sources, such as pluripotent stem cells or somatic cells. Also provided are therapeutic compositions including the provided hematopoietic cells and precursors of hematopoietic cells, and methods of using such for the treatment of subjects. | 2014-02-06 |
| 20140037601 | NUTRITIONAL COMPOSITIONS INCLUDING BRANCHED CHAIN FATTY ACIDS FOR WOUND HEALING - Nutritional compositions for improving, treating and/or preventing various medical conditions and methods of using same are provided. The medical conditions may include wounds, mucositis among others. The nutritional compositions include branched chain fatty acids and may include other functional ingredients such as, but not limited to probiotics, nucleotides and amino acids. Methods of administering such nutritional products to individuals in need of same are also provided. | 2014-02-06 |
| 20140037602 | NUTRITIONAL COMPOSITIONS INCLUDING BRANCHED CHAIN FATTY ACIDS AND METHODS OF USING SAME - Nutritional compositions for improving, treating and/or preventing various medical conditions and methods of using same are provided. The medical conditions may include allergies, autoimmune diseases, among others. The nutritional compositions include branched chain fatty acids and may include other functional ingredients such as, but not limited to probiotics, nucleotides and amino acids. Methods of administering such nutritional products to individuals in need of same are also provided. | 2014-02-06 |
| 20140037603 | NUTRITIONAL COMPOSITIONS INCLUDING BRANCHED CHAIN FATTY ACIDS FOR IMPROVING GUT BARRIER FUNCTION - Nutritional compositions for improving, treating and/or preventing various medical conditions and methods of using same are provided. Such medical conditions include infection, sepsis, malabsorption, allergy, inflammatory bowel disease, and diarrhea among others. The nutritional compositions include branched chain fatty acids and may include other functional ingredients such as, but not limited to probiotics, nucleotides and amino acids. Methods of administering such nutritional products to individuals in need of same are also provided. | 2014-02-06 |
| 20140037604 | NUTRITIONAL COMPOSITIONS COMPRISING ALPHA-HYDROXYISOCAPROIC ACID - Nutritional compositions for maximizing muscle protein synthesis while minimizing the catabolism of muscle proteins and methods of using same are provided. In this manner, the nutritional compositions may provide for retention of lean body mass, which helps to avoid loss of independence and functionality, as well as to improve quality of life especially in the elderly at risk of sarcopenia and frailty. The nutritional compositions include α-hydroxyisocaproic acid and may include other functional ingredients such as, but not limited to whey protein including whey protein micelles, prebiotic fibers, L-carnitine, nucleotides, and amino acids. Methods of administering such nutritional products to individuals in need of same are also provided. | 2014-02-06 |
| 20140037605 | ANTICOCCIDIAL COMPOSITION - [Objects] An object of the present invention is to provide an orally administrable agent for medical use for animals for preventing or treating coccidiosis which is highly safe with no side effects, an agent for a food or a drink for use in the preservation of health, a feed additive, and a feed comprising the same. Another object of the present invention is to provide a method for rearing animals (particularly, livestock and poultry) using the same and a method for controlling coccidiosis using the same. | 2014-02-06 |
| 20140037606 | CELL-BASED, ANTI-CANCER VACCINES - The present invention relates to cancer vaccines and more particularly to compositions and methods for producing activated antigen presenting cells (dendritic cells, macrophages, monocytes, or other cells capable of presenting antigen to T lymphocytes); to pharmaceutical compositions including such cells; and to methods of using such cells (e.g., in treating patients who are suffering from or at risk of developing cancer). | 2014-02-06 |
| 20140037607 | CULTURE MEDIUM AND METHOD FOR OBTAINING A POPULATION OF TOLEROGENIC DENDRITIC CELLS - The present invention relates to a culture medium suitable for inducing dendritic cell differentiation comprising an effective amount of secretory immunoglobulins A (SIgA) and also to a method for obtaining a population of tolerogenic dendritic cells from cells, in particular monocytes. The present invention relates to uses of tolerogenic dendritic cells thus obtained in therapy and in induction of transplant tolerance. | 2014-02-06 |
| 20140037608 | INSECTICIDAL PROTEIN, GENE ENCODING THE SAME AND USES THEREOF - The invention relates to an insecticidal protein, its gene encoding and the uses thereof. The protein comprises: (a) a protein consisting of an amino acid sequence shown by SEQ ID NO:2; or (b) a protein derived from (a) consisting of an amino acid sequence by substitution, deletion, or addition of one or more amino acid residues of the amino acid sequences in (a), and having insecticidal activity; or (c) a protein generated by the expression of nucleic acid molecules containing a nucleotide sequence of SEQ ID NO:1; or (d) a protein generated by the expression of nucleic acid molecules containing a complementary sequence that hybridized with SEQ ID NO:1 under stringent conditions; or (e) a protein generated by the expression of nucleic acid molecules that contain nucleotide sequences isocoding with the nucleotide sequences in (d). The insecticidal protein of the invention has high expression level and strong toxicity against pests. | 2014-02-06 |
| 20140037609 | INSECTICIDAL PROTEIN, GENE ENCODING THE SAME AND USES THEREOF - The invention relates to an insecticidal protein, its gene encoding and the uses thereof. The protein comprises: (a) a protein consisting of an amino acid sequence shown by SEQ ID NO:2 or a sequence of amino acid residuses at positions 1 to 640 thereof; or (b) a protein derived from (a) by substitution, deletion, or addition of one or more amino acid residuses of the amino acid sequences in (a), and having insecticidal activity; or (c) a protein generated by the expression of nucleic acid molecules containing a sequence of amino acid residuses at the positions 1 to 1920 of SEQ ID NO:1; or (d) a protein generated by the expression of nucleic acid molecules containing a complementary sequence that hybridized with the sequence of nucleotides at the positions 1 to 1920 of SEQ ID NO:1 under stringent conditions. The protein has high expression level and strong toxicity against pests. | 2014-02-06 |
| 20140037610 | METHODS OF TREATING INFECTIONS ORIGINATING FROM VIRUSES IN THE HERPESVIRIDAE FAMILY - Three RNases (ranpirnase, the second embodiment disclosed in U.S. Pat. No. 5,728,805, and recombinant Amphinase-2) are tested against identified herpesviridae infections. With some exceptions, quantitative PCR assays indicate that the RNases have anti-viral activity against many of these viruses. | 2014-02-06 |
| 20140037611 | Treatment of Pompe's Disease - The invention provides methods of treating Pompe's disease using human acid alpha glucosidase. A preferred treatment regime comprises administering greater than 10 mg/kg body weight per week to a patient. | 2014-02-06 |
| 20140037612 | SUBCUTANEOUS ADMINISTRATION OF ALPHA-GALACTOSIDASE A - The invention relates, in part, to improved methods of administering α-galactosidase A for the treatment of α-galactosidase A deficiencies including Fabry disease. | 2014-02-06 |
| 20140037613 | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases - The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated form of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity. | 2014-02-06 |
| 20140037614 | THERAPEUTIC AND PROPHYLACTIC METHODS, USES AND COMPOSITIONS COMPRISING ANEXIN A5 - The present invention provides a method for the prevention and/or reduction of peri- or postoperative complications following surgical intervention, such as complications following vascular surgery, especially peripheral vascular surgery, comprising administering a therapeutically effective amount of Annexin (A5) or a functional analogue or variant thereof to a patient in need of such treatment, Also provided is a pharmaceutical composition comprising a therapeutically effective amount of Annexin (A5) or a functional analogue or variant thereof for use in the prevention and/or reduction of peri- or postoperative complications following surgical intervention, such as complications following vascular surgery, especially peripheral vascular surgery. | 2014-02-06 |
| 20140037615 | MATERIALS AND METHODS FOR DESIGNING AUTOLOGOUS IDIOTYPE VACCINES AND TREATMENT OF B-CELL MALIGNANCIES - The present invention relates to compositions, kits, and methods for preparing an autologous idiotype vaccine, or autologous anti-idiotype vaccine, for treatment of a B-cell malignancy based on the isotype(s) (class(es)) of immunoglobulins expressed by the malignancy; methods for treating B-cell malignancies; and methods for selecting a treatment for a subject having a B-cell malignancy. | 2014-02-06 |
| 20140037616 | IMMUNOGLOBULIN 1 - The present invention relates to a method for the generation of single chain immunoglobulins in a mammal. In particular, the present invention relates to a method for the generation of single chain camelid VHH antibodies in a mammal which undergo the process of class-switching and affinity maturation found within antibody producing B cells. Single chain antibodies generated using the method of the present invention and the uses thereof are also described. | 2014-02-06 |
| 20140037617 | KINASE MODULATION, AND INDICATIONS THEREFOR - The present disclosure provides methods of using protein kinase inhibitors for treating diseases and conditions, including diseases and conditions associated with activity of any protein kinase selected from Fms protein kinase including any mutations thereof, Kit protein kinase any mutations thereof, Flt-3 protein kinase any mutations thereof and combinations thereof. | 2014-02-06 |
| 20140037618 | METHOD OF TREATING AUTOIMMUNE INFLAMMATORY DISORDERS USING IL-23R LOSS-OF-FUNCTION MUTANTS - The present invention relates to compositions and methods of diagnosing and treating autoimmune and inflammatory disorders that are characterized by IL-23R loss-of-function mutations. | 2014-02-06 |
| 20140037619 | MIMOTOPES OF HIV ENV - The invention provides methods, compositions and kits for treating and or preventing an HIV infection. For example, HIV envelope-like polypeptides (wild-type HIV polypeptides and mimotopes) may be administered to an individual so as to induce a protective immune response to HIV. Alternatively, antibodies directed to the HIV envelope-like polypeptides may be administered to an individual to treat or prevent an HIV infection and/or one or more symptoms associated with the infection (e.g., AIDS). | 2014-02-06 |
| 20140037620 | Methods of Treating Breast Cancer with Gemcitabine Therapy - The application describes methods for predicting overall survival in subjects with breast cancer. The application also describes for screening subjects with breast cancer to determine if the breast cancer will be responsive to a breast cancer therapy including gemcitabine. The application further describes methods for treating subjects with breast cancer by screening them for the likelihood of the effectiveness of treating the cancer with a therapy including gemcitabine and administering the therapy in subjects when it is found that gemcitabine is likely to be effective. | 2014-02-06 |
| 20140037621 | ANTIBODIES OR FUSION PROTEINS MULTIMERIZED VIA CYSTEINE MUTATION AND A MU TAILPIECE - The invention provides constant regions incorporating a cysteine mutation and linked to a μ tailpiece and antibodies or fusion proteins incorporating the same. The constant regions include at least CH2 and CH3 regions of an IgG heavy chain constant region including a cysteine mutation and μ tailpiece. Antibodies or fusion proteins incorporating the constant regions gains the ability to form multivalent complexes, e.g., pentameric or hexameric structures. Antibodies or fusion proteins incorporating the constant regions also retain IgG properties including specific binding to protein G, which facilitates purification and may exhibit pH-dependent FcRn binding, which is associated with a relatively long in vivo half-life. Depending on the isotype and subtype, the nature of the antigen and presence of an additional IgG hinge domain, such antibodies or fusion proteins may also have properties of specific binding to protein A, and effector functions such as ADCC, CDC and opsonization. | 2014-02-06 |
| 20140037622 | HUMAN PAPILLOMA VIRUS AS PREDICTOR OF CANCER PROGNOSIS - Methods of treating a head and neck cancer are disclosed. | 2014-02-06 |
| 20140037623 | Pharmaceutical Compositions Comprising Antibodies Binding To EBV (Ebstein-Barr Virus) Protein BARF1 - The invention relates to pharmaceutical and vaccine compositions comprising an antibody binding specifically to selected peptides of EBV protein BARF1. | 2014-02-06 |
| 20140037624 | ANTI-FGFR4 ANTIBODIES AND METHODS OF USE - The invention provides anti-FGFR4 antibodies and methods of using the same. | 2014-02-06 |
| 20140037625 | BIOMARKERS AND METHODS OF TREATMENT - The present invention concerns cancer biomarkers. In particular, the invention concerns c-met as biomarkers for patient selection and patient prognosis in cancer, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, methods of detection and methods of advertising related thereto. | 2014-02-06 |
| 20140037626 | Metal Abstraction Peptide With Release of Metal - Compositions comprising peptides that are capable of binding a metal in a square planar orientation, a square pyramidal orientation, or both, are disclosed. Such compositions can be used for binding and releasing a metal in a variety of contexts and environments, such as the treatment of cancer. | 2014-02-06 |
| 20140037627 | MODULATION OF PILR RECEPTORS TO TREAT MICROBIAL INFECTIONS - The present invention provides methods of using agonists and antagonists of PILRα and PILRβ, respectively, to treat | 2014-02-06 |
| 20140037628 | ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III CHIMERIC ANTIGEN RECEPTORS AND USE OF SAME FOR THE TREATMENT OF CANCER - The disclosure provides chimeric antigen receptors (CARs) comprising an antigen binding domain of human antibody 139, an extracellular hinge domain, a transmembrane domain, and an intracellular domain T cell receptor signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are also disclosed. | 2014-02-06 |
| 20140037629 | HUMANIZED SINGLE-CHAIN ANTIBODY AGAINST BETA 3 INTEGRIN FOR THE TREATMENT AND PREVENTION OF METASTASIS - The present invention relates to methods inhibiting tumor metastasis and treating cancer in a subject that involve administering to the subject an antibody which recognizes GPIIIa49-66, under conditions effective to inhibit tumor metastasis and/or treat cancer in the subject. | 2014-02-06 |
| 20140037630 | METHODS FOR TREATING MICA-RELATED DISORDERS - Disclosed herein are materials and methods for treating cancer. In particular, the compositions and methods for treating cancers associated with MICA overexpression are provided. | 2014-02-06 |
| 20140037631 | ANTIGEN BINDING FORMATS FOR USE IN THERAPEUTIC TREATMENTS OR DIAGNOSTIC ASSAYS - The present invention relates to antigen binding formats for use in therapeutic treatments or diagnostic assays. The present invention relates to an antigen-binding format consisting of: a first fusion protein wherein the CH1 constant domain of an antibody is fused i) by its N-terminal end to the C-terminal end of a variable domain of an antibody and ii) by its C-terminal end to the N-terminal end of a variable domain of an antibody and, a second fusion protein wherein the CL constant domain of an antibody is fused by its N-terminal end to the C-terminal end of a variable domain of an antibody. | 2014-02-06 |
| 20140037632 | MULTI-SPECIFIC ANTIGEN-BINDING MOLECULES AND USES THEREOF - Various bispecific antibodies that specifically bind to both blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X and functionally substitute for the cofactor function of blood coagulation factor VIII, that is, the function to promote activation of blood coagulation factor X by activated blood coagulation factor IX, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor VIII were successfully discovered. | 2014-02-06 |
| 20140037633 | METHODS AND COMPOSITIONS RELATING TO SYNTHETIC BETA-1,6 GLUCOSAMINE OLIGOSACCHARIDES - The invention relates to the compositions of synthetic oligo-β-(1→6)-2-amino-2-deoxy-D-glucopyranosides conjugated to carriers, and methods for making and use same. | 2014-02-06 |
| 20140037634 | REGULATORY T CELL MEDIATOR PROTEINS AND USES THEREOF - The present invention relates to novel regulatory T cell proteins. One protein, designated PD-L3, resembles members of the PD-L1 family, and co-stimulates αCD3 proliferation of T cells in vitro. A second, TNF-like, protein has also been identified as being upregulated upon αCD3/αGITR stimulation. This protein has been designated T | 2014-02-06 |
| 20140037635 | METHODS OF TREATMENT USING IL-17E ANTAGONISTS - Novel IL-17 like polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, selective binding agents, and methods for producing IL-17 like polypeptides. Also provided for are methods for the treatment, diagnosis, amelioration, or prevention of diseases with IL-17 like polypeptides, agonists, or antagonists thereof. | 2014-02-06 |
| 20140037636 | ANTI-CD98 ANTIBODY PROCESSES - A human antibody or a functional fragment thereof having specific binding ability to CD98 which is derived from the cell membrane of cancer cells and is in the form of a complex with a protein having an amino acid transporter activity (for example, LAT1) is disclosed. This antibody binds to CD98 in the form of a dimer with LAT1 on the surface of cancer cells, specifically attacks cancer cells expressing CD98 via the immune system by ADCC or CDC, and further inhibits amino acid uptake of the cancer cells via LAT1, to suppress growth of the cancer cells. Accordingly, a preventive and therapeutic agent for cancer comprising this antibody or a fragment thereof, which acts on various cancers, is specific to cancer, and causes no side effect, is provided. | 2014-02-06 |
| 20140037637 | MITIGATING TISSUE DAMAGE AND FIBROSIS VIA LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN (LTBP4) - The disclosure relates to compositions and methods of mitigating tissue damage and fibrosis in a patient by modulating latent transforming growth factor beta binding protein (LTBP4)-induced proteolysis of a TGFβ superfamily protein. | 2014-02-06 |
| 20140037638 | COMPOSITIONS AND METHODS FOR TREATING AMYLOID PLAQUE ASSOCIATED SYMPTOMS - The present invention encompasses compositions and methods for effectively treating at least one symptom or sign of A plaque associated symptoms or for decreasing amyloid plaque loads. The method comprises administering an effective amount of an anti-ApoE antibody to a living mammalian biosystem such as to a human. | 2014-02-06 |
| 20140037639 | LINGO Binding Molecules and Pharmaceutical Use Thereof - The present invention provides a binding molecule which is capable of binding to the rat, cynomolgus monkey and human LINGO polypeptide, a polynucleotide encoding such binding molecule; an expression vector comprising said polynucleotide; an expression system comprising a polynucleotide capable of producing a binding molecule; an isolated host cell which comprises an expression system as defined above; the use of such binding molecule as a pharmaceutical, especially in the treatment to promote axonal regeneration/plasticity; a pharmaceutical composition comprising said binding molecule; and a method of treatment of diseases associated with axonal degeneration and demyelination. | 2014-02-06 |
| 20140037640 | COMPOSITION COMPRISING EXPRESSION OR ACTIVITY INHIBITORS OF NINJURIN1 FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISEASE - The present invention relates to a composition comprising a Ninjurin1 expression or activity inhibitor for the prevention and treatment of inflammatory disease. Ninjurin1 protein is specifically expressed in macrophages around blood vessels, increases cell-cell adhesion and cell-matrix adhesion, increases expressions of Wnt7b (Wingless-type MMTV integration site family, member 7B) and Ang2 (angiopoietin-2), but reduces expression of Ang1 to induce apoptosis of vascular endothelial cells. In addition, Ninjurin1 protein is up-regulated when inflammation is induced and induces iNOS expression as well as increased NO generation. Therefore, the Ninjurin1 protein expression or activation inhibitor can be effectively used as an active ingredient of a composition for the prevention and treatment of inflammatory disease. | 2014-02-06 |
| 20140037641 | Peptide and Conjugate Vaccines for Fungal Infections - Several new peptides have been developed that show effectiveness as vaccines against candidiasis and other fungal diseases. A new conjugate vaccine of a β-mannotriose linked to a fungal peptide linked to tetanus toxin has been shown to be effective as a vaccine with or without use of an adjuvant. In addition, a monoclonal antibody has been identified that offers protection from a | 2014-02-06 |
| 20140037642 | METHODS AND COMPOSITIONS RELATING TO INHIBITION OF IGF-1R - The present invention provides, in part, methods for treating a tumor in a human subject comprising inhibiting IGF-1 receptor signaling, methods of determining whether a tumor is more or less likely to respond to such treatment, and compositions for practicing such methods. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-1R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions, and kits for practicing the foregoing. | 2014-02-06 |
| 20140037643 | ANTI-NOTCH2 NRR ANTIBODIES - The invention provides anti-Notch antibodies, and in particular, antibodies that bind Notch2 NRR, and methods of using the same. | 2014-02-06 |
| 20140037644 | Prospective Identification and Characterization of Breast Cancer Stem Cells - The invention provides methods for treating cancer via administering to a patient having a solid tumor a therapeutically effective amount of an antibody against Delta-like ligand 4(Dll4) or other Notch pathway components. The solid tumor may comprise solid tumor stem cells. | 2014-02-06 |
| 20140037645 | DIAGONSIS AND TREATMENT OF AUTOIMMUNE DISEASES BY TARGETING AUTOIMMUNE-RELATED B CELLS ("ABCS") - The present invention is directed to methods of diagnosis and treatment of autoimmune diseases based on the identification of a novel population of B cells known as Autoimmune- or Age-related B cells (“ABCs”). These cells express the CDI Ic cell surface protein and exhibit a unique gene expression profile. The ABCs increase in numbers in subjects that are prone to developing autoimmune diseases or in healthy individuals, particularly females, as they age. Accordingly, the present invention includes methods and kits for diagnosis of autoimmune diseases based on the detection of the ABCs before overt symptoms of the disease become detectable. The present invention also includes methods of treatment of autoimmune diseases by targeting the ABCs, as well as methods for assessing the efficacy of treatments of autoimmune diseases. | 2014-02-06 |
| 20140037646 | MMP8 INACTIVATING ANTIGEN BINDING PROTEINS - Described are MMP8 inactivating antigen binding proteins, such as antigen binding proteins comprising an amino acid sequence that comprises 4 framework regions and 3 complementary determining regions; further described is the use of such antigen binding proteins to treat inflammation, such as, but not limited to, systemic inflammatory response syndrome, sepsis, LPS induced inflammation, renal ischemia/reperfusion injury, ventilation induced lung injury, periodontal inflammation, rheumatoid arthritis, multiple sclerosis, ankylosing spondylitis, Lyme arthritis and osteoarthritis. | 2014-02-06 |
| 20140037647 | MOLECULAR SUBTYPING, PROGNOSIS AND TREATMENT OF PROSTATE CANCER - Disclosed herein are new prognostic molecular markers for prostate cancer. More specifically, the invention has identified that overexpression or amplification of at least one of AURKA or MYCN define a distinct subgroup of prostate cancer that is predisposed to the development of lethal NEPC, who will benefit from early intervention. | 2014-02-06 |
| 20140037648 | ANTIBODIES THAT NEUTRALIZE RSV, MPV AND PVM AND USES THEREOF - The invention relates to antibodies, and antigen binding fragments thereof, that neutralize infection of both RSV, MPV and PVM. The invention also relates to nucleic acids that encode, immortalized B cells and cultured plasma cells that produce, and to polypeptides that bind to such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and polypeptides recognized by the antibodies of the invention in screening methods as well as in the diagnosis, treatment and prevention of RSV or MPV infection and RSV and MPV co-infection. | 2014-02-06 |
| 20140037649 | DIAGNOSTIC AND/OR SCREENING AGENTS AND USES THEREFOR - Disclosed are methods and apparatus for diagnosis, detection of host response, monitoring, treatment or management of sepsis, infection-negative systemic inflammatory response syndrome (SIRS) and post-surgical inflammation in mammals. More particularly, the present invention discloses marker genes and their splice variant transcripts as well as their expression products, which are useful for distinguishing between sepsis and infection-negative SIRS, including post-surgical inflammation, and to the use of these markers in grading, monitoring, treatment and management of these conditions. | 2014-02-06 |
| 20140037650 | COMPOSITIONS AND METHODS RELATED TO ANTIBODIES TO STAPHYLOCOCCAL PROTEINS ISDA OR ISDB - The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a | 2014-02-06 |
| 20140037651 | DEPLETED ANTI-STAPHYLOCOCCAL ENTEROTOXINS POLYCLONAL ANTIBODIES, PREPARATION AND USES THEREOF - The present invention relates to the preparation of a set of depleted polyclonal antibodies, each depleted polyclonal antibody being raised against one specific staphylococcal enterotoxin, and its use for multiplex detection. | 2014-02-06 |
| 20140037652 | Detection and Treatment of Polycystic Kidney Disease - Compositions useful for examining the PKD1 gene are provided. In addition, methods for detecting mutations of the PKD1 gene, which can be associated with autosomal dominant polycystic kidney disease in humans, are provided. Methods for diagnosing a mutant PKD1 gene sequence in a subject also are provided, as are methods of treating a subject having a PKD1-associated disorder. | 2014-02-06 |
| 20140037653 | MODULATION OF LRCH4 ACTIVITY AND THERAPEUTIC APPLICATION THEREOF - Disclosed herein are methods for altering cellular functions and processes by modulating the activity of Lrch4. Corresponding compositions that may be used in carrying out the described methods are also disclosed as are related methods of treatment for relevant diseases and physiological states. | 2014-02-06 |
| 20140037654 | THERAPEUTIC METHOD AND MEDICAMENT FOR HTLV-1 ASSOCIATED MYELOPATHY (HAM) - The object of the present invention is to provide a new therapeutic method and a new therapeutic agent that are different from known therapeutic medicines for human T cell leukemia virus type-1 associated myelopathy (HAM) patients and asymptomatic HTLV-1 carriers. The present invention relates to a therapeutic method and a therapeutic agent for human T cell leukemia virus type-1 (HTLV-1) associated myelopathy (HAM) patients and asymptomatic HTLV-1 carriers (ACs), which is characterized by reducing HTLV-1 virus-infected cells using an anti-human CC-chemokine receptor 4 (CCR4) antibody. | 2014-02-06 |
| 20140037655 | USE OF NUCLEOLIN AS A BIOMARKER FOR LYMPHANGIOGENESIS IN A CANCER PROGNOSIS AND THERAPY - The present invention relates to a method of identifying cancer subjects, in particular human patients, who are suitable for anti-lymphangiogenesis therapy to prevent tumor growth and tumor metastasis. The present invention also relates to a new approach, which uses nucleolin as a bait to search and screen for lymphangiogenesis inhibitors or cancer suppressors, which function in a manner that is analogous to endostatin. The invention is based upon the discovery that nucleolin is specifically expressed on lymphangiogenic vessels and functions as a specific receptor for endostatin, and thus is involved in the signal transduction pathway of endostatin as an anti-lymphangiogenesis inhibitor. The present invention also discloses that cell surface nucleolin on lymphatic endothelial cells is a biomarker for lymphangiogenic vessels, which could be used for the prediction of tumor metastasis. | 2014-02-06 |
| 20140037656 | Treatment for Tauopathies - A method is described to treat tauopathies by extracorporeally treating a patient's cerebrospinal fluid (CSF). The method includes introducing an antibody into the CSF that is targeted to an antigen associated with tauopathies. The antibody can include an albumin moiety, and targets the removal of antigens such as tau protein, phosphorylated tau (pTau) protein, Ubiquitin and PKN. The antibody-antigen complex can be removed from the CSF and the CSF can be returned to the patient. | 2014-02-06 |
| 20140037657 | INHIBITION OF TUMOR GROWTH - The present invention provides a cytotoxic 7 to 25 mer peptide with three or more cationic residues which has one or more non-genetic bulky and lipophilic amino acids, as well as esters, amides, salts and cyclic derivatives thereof as well as methods of preparing the peptides, pharmaceutical compositions containing them and their use as medicaments, particularly as antibacterions or antitumoral agents. In a preferred aspect, the invention provides the use of said peptides in a method of inducing adaptive immunity against tumor growth or establishment in a subject, as well as the use of other lytic agents in a method of inducing adaptive immunity in a subject. | 2014-02-06 |
| 20140037658 | Diagnosis and Treatment of Alzheimer's Disease - Methods are provided for the prevention, treatment and diagnosis of Alzheimer's disease, based on the glycosylation pattern of amyloid-beta peptides in body fluids and tissues. | 2014-02-06 |
| 20140037659 | SNX9 AS A NOVEL BIOMARKER FOR CHRONIC INFLAMMATION AND ASSOCIATED IMMUNOSUPPRESION AND A NEW REGULATOR OF T CELL RECEPTOR EXPRESSION AND FUNCTION - The present invention relates to diagnostic and prognostic methods and kits for assessing chronic inflammation and associated immune-suppression. More particularly, the invention relates to the use of SNX9 (sorting nexin 9 protein) as a biomarker for chronic inflammation and associated immune-suppression, specifically, in subjects suffering from chronic inflammatory conditions. The invention further provides a prognostic tool for detecting regression or recurrence of the diseases and a powerful tool for assessing efficacy of a treatment. The present invention further provides SNX9 as an immunomodulator and therefore relates to methods for treating immune-related disorders by modulating SNX9 expression. | 2014-02-06 |
| 20140037660 | COMPLEXES OF RNA AND CATIONIC PEPTIDES FOR TRANSFECTION AND FOR IMMUNOSTIMULATION - The present invention relates to a complexed RNA, comprising at least one RNA complexed with one or more oligopeptides, wherein the oligopeptide, which has the function of cell-penetrating peptide (CPP), has a length of 8 to 15 amino acids and has the empirical formula (Arg) | 2014-02-06 |
| 20140037661 | Wheat Antigens and Peptides for Diagnosis of Wheat Induced Hypersensitivity - The present invention relates to the field of different wheat hypersensitivities, particularly with antigens and peptides for discrimination of different forms of these diseases. The invention relates to the identification of novel wheat allergens and the use thereof in therapy and diagnosis of celiac disease, dermatitis herpetiformis, and IgE-mediated allergy. Furthermore, the present invention provides the use of known peptides and proteins in therapy and diagnosis. The invention also relates to methods for diagnosis and treatment of celiac disease, dermatitis herpetiformis, and IgE-mediated allergy. | 2014-02-06 |
| 20140037662 | METHODS AND COMPOSITIONS FOR INDUCING AN IMMUNE RESPONSE TO EGFRVIII - The present invention relates to methods of inducing a T-cell response against a EGFRvIII in a subject. These method comprise administering to a subject a composition which expresses at least one immunogenic polypeptide, the amino acid sequence of which comprise a plurality of EGFRvIII polypeptide sequences, the sequence of which each comprise EEKKGNYV (SEQ ID NO: 3), and/or administering the polypeptide itself. | 2014-02-06 |
| 20140037663 | HYPOALLERGEN - The present invention provides mutant polypeptides useful as hypoallergens. More specifically the present invention provides mutant Bet v 1 proteins and the use of such polypeptides as hypoallergens for desensitizing against birch pollen allergies. Furthermore, the invention provides vaccine formulations comprising such polypeptides; the use of such formulations; and to methods of vaccination against birch pollen allergy. | 2014-02-06 |
| 20140037664 | PROTEIN FOR USE AS A MEDICAMENT - The present invention pertains to a protein having the characteristics of a serine protease having an amino acid sequence according to SEQ ID NO 2 for use as a medicament. The invention also pertains to this protein for use in a vaccine to protect an animal against an infection with a micro organism that secretes said protein, and to the corresponding antibodies directed against the protein. | 2014-02-06 |
| 20140037665 | PESTIVIRUS SPECIES - The application relates to a | 2014-02-06 |
| 20140037666 | COMPOSITIONS FOR PREVENTING AND/OR TREATING AN INFECTION BY AN HIV-1 VIRUS - The present invention relates to an immunogenic composition comprising an antigenic peptide of formula (I) below: Nt-S—X1-X2-X3-K—X4-Ct (I) [SEQ ID No 1], wherein—Nt consists of a peptide having from 0 to 50 amino acids in length, —Ct consists of a peptide having from 0 to 50 amino acids in length, —each of X1 to X4 consists of an amino acid residue, wherein: —(i) X1 means the specific amino acid W or (ii) X1 means any amino acid residue excepted W, —(i) X2 means the specific amino acid S or (ii) X2 means any amino acid residue excepted S, —(i) X3 means the specific amino acid N or (ii) X3 means any amino acid residue excepted N, —(i) X4 means the specific amino acid S or (ii) X4 means any amino acid residue excepted S, with the proviso that—three out of the four amino acid residues X1, X2, X3 and X4 mean the specific amino acid defined in their respective meaning (i) above, and—the remaining amino acid residue among X1 to X4 means any amino acid residue excepted the specific amino acid residue defined in its meaning (i), for preventing and/or treating an infection of an individual with an HIV-1 virus. | 2014-02-06 |
| 20140037667 | RAPID SELECTION METHOD FOR HIV GP-120 VARIANTS - The invention relates to a method for rapid immunogen selection (RIS) based on the binding a library of recombinant viruses containing randomized HIV gp120 variants of a surface polypeptide displayed to said neutralizing antibodies. The invention relates as well to the use of the HIV gp120 immunogens isolated according to the RIS method of the invention in medicine for the treatment of diseases caused by a virus and in diagnosis for the identification of neutralizing antibodies in a patient. | 2014-02-06 |
| 20140037668 | COMBINATION NEISSERIAL COMPOSITIONS - Compositions comprising a first biological molecule from a | 2014-02-06 |
| 20140037669 | MULTICOMPONENT IMMUNOGENIC COMPOSITION FOR THE PREVENTION OF BETA-HEMOLYTIC STREPTOCOCCAL (BHS) DISEASE - A number of β-hemolytic streptococci polynucleotides and polypeptides, particularly | 2014-02-06 |
| 20140037670 | CYAA-CARRIED POLYPEPTIDE(S) AND USE TO INDUCE BOTH THERAPEUTIC AND PROPHYLACTIC IMMUNE RESPONSES - The invention is directed to means, based on CyaA-carried polypeptide(s), for use in the immunotherapeutic treatment of first determined pathological condition(s) diagnosed in a mammalian host by eliciting a T cell immune response against a first group of epitopes contained in said polypeptide(s) and in the prophylaxis against second determined pathological condition(s) in the same mammalian host by eliciting a T cell memory immune response against a second group of epitopes contained in said polypeptide(s), said immune responses being obtained after administration of said vector-carried polypeptide(s) into said host, wherein said prophylaxis against second determined pathological condition(s) is not observed when said second group of epitopes is not contained in said administered vector-carried polypeptide(s). | 2014-02-06 |
| 20140037671 | IMMUNOGENIC COMPOSITIONS FOR STREPTOCOCCUS PYOGENES - The invention includes a GAS antigen, GAS 40, which is particularly suitable for use either alone or in combinations with additional GAS antigens, such as GAS 117, GAS 130, GAS 277, GAS 236, GAS 40, GAS 389, GAS 504, GAS 509, GAS 366, GAS 159, GAS 217, GAS 309, GAS 372, GAS 039, GAS 042, GAS 058, GAS 290, GAS 511, GAS 533, GAS 527, GAS 294, GAS 253, GAS 529, GAS 045, GAS 095, GAS 193, GAS 137, GAS 084, GAS 384, GAS 202, and GAS 057. | 2014-02-06 |
| 20140037672 | FUSION PROTEINS COMPRISING ANTIGENIC APOB-100 PROTEIN FRAGMENTS AND A PROTEIN CARRIER, RELATED COMPOSITIONS, METHODS AND SYSTEMS FOR TREATMENT AND/OR PREVENTION OF ATHEROSCLEROSIS - A fusion protein comprising an antigenic fragment of apoB-100 and a suitable carrier and related compositions methods and systems. | 2014-02-06 |
| 20140037673 | POLYVALENT CONJUGATE VACCINE FOR CANCER - This invention provides a polyvalent vaccine comprising at least two conjugated antigens selected from a group containing glycolipid antigen, polysaccharide antigen, mucin antigen, glycosylated mucin antigen and an appropriate adjuvant. This invention also provides a multivalent vaccine comprising at least two of the following: glycosylated MUC-1-32mer, Globo H, GM2, Le | 2014-02-06 |
| 20140037674 | ORAL ADMINISTRATION OF MELANIN FOR PROTECTION AGAINST RADIATION - Methods and compositions are provided for alleviating and/or preventing one or more side effects associated with exposure to radiation in a subject exposed to radiation or at risk for exposure to radiation comprising oral administration to the subject of an amount of an edible source of melanin effective to alleviate a side effect associated with radiation. | 2014-02-06 |
| 20140037675 | PROCESS FOR PREPARING METABOLIZED CONDITIONED GROWTH MEDIA - Compositions comprising metabolized conditioned growth medium and/or metabolized cell extract and methods of use are described. The metabolized conditioned growth medium and metabolized cell extract compositions may be formulated with an acceptable carrier into injectable or topical formulations, for example, as a cream, lotion or gel, and may be used in cosmeceutical or pharmaceutical applications. The metabolized conditioned growth medium and metabolized cell extract may also be further processed to concentrate or reduce one or more factors or components contained within the metabolized conditioned growth medium or metabolized cell extract. The growth medium may be conditioned by any eukaryotic cell. The metabolized conditioned growth medium and metabolized cell extract may be used to prevent or treat a condition, for example, a skin condition. | 2014-02-06 |
| 20140037676 | PROCESS FOR PREPARING METABOLIZED CONDITIONED GROWTH MEDIA - Compositions comprising metabolized conditioned growth medium and/or metabolized cell extract and methods of use are described. The metabolized conditioned growth medium and metabolized cell extract compositions may be formulated with an acceptable carrier into injectable or topical formulations, for example, as a cream, lotion or gel, and may be used in cosmeceutical or pharmaceutical applications. The metabolized conditioned growth medium and metabolized cell extract may also be further processed to concentrate or reduce one or more factors or components contained within the metabolized conditioned growth medium or metabolized cell extract. The growth medium may be conditioned by any eukaryotic cell. The metabolized conditioned growth medium and metabolized cell extract may be used to prevent or treat a condition, for example, a skin condition. | 2014-02-06 |
| 20140037677 | PROCESS FOR PREPARING METABOLIZED CONDITIONED GROWTH MEDIA - Compositions comprising metabolized conditioned growth medium and/or metabolized cell extract and methods of use are described. The metabolized conditioned growth medium and metabolized cell extract compositions may be formulated with an acceptable carrier into injectable or topical formulations, for example, as a cream, lotion or gel, and may be used in cosmeceutical or pharmaceutical applications. The metabolized conditioned growth medium and metabolized cell extract may also be further processed to concentrate or reduce one or more factors or components contained within the metabolized conditioned growth medium or metabolized cell extract. The growth medium may be conditioned by any eukaryotic cell. The metabolized conditioned growth medium and metabolized cell extract may be used to prevent or treat a condition, for example, a skin condition. | 2014-02-06 |
| 20140037678 | COMPOSITION FOR TREATING OBESITY AND METHOD OF USING THE SAME - The present invention provides a composition for a medicinal or health effect of a treatment of liver fat and body fat, a reduction of blood pressure, an increase of the energy expenditure rate, a reduction of inflammatory C-reactive proteins and a reduction of plasma aminotransferase enzymes, comprising an effective amount of fucoxanthin alone or in combination with pomegranate seed oil, a pharmaceutically acceptable salt, a prodrug thereof, or a salt of the prodrug; and a method of using the same. The fucoxanthin may be used in pure form, or as a component of a brown marine vegetable extract. | 2014-02-06 |
| 20140037679 | Immunization of avians by administration of non-replicating vectored vaccines - The present invention relates generally to the fields of immunology and vaccine technology. More specifically, the invention relates to recombinant human adenovirus vectors for delivery of avian immunogens and antigens, such as avian influenza into avians. The invention also provides methods of introducing and expressing an avian immunogen in avian subjects, including avian embryos, as well as methods of eliciting an immunogenic response in avian subjects to avian immunogens. | 2014-02-06 |
| 20140037680 | NOVEL METHOD - This disclosure provides methods for protecting infants against disease caused by respiratory syncytial virus (RSV) through maternal immunization using recombinant respiratory syncytial virus (RSV) antigens to reduce the incidence or severity of RSV infection in young infants. | 2014-02-06 |
| 20140037681 | HIV-1 ENVELOPE GLYCOPROTEIN - The present application relates to novel HIV-1 envelope glycoproteins which may be utilized as an HIV-1 vaccine immunogens, antigens for crystallization and for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention. | 2014-02-06 |
| 20140037682 | HIV/SIV VACCINES FOR THE GENERATION OF MUCOSAL AND SYSTEMIC IMMUNITY - Compositions of genetically engineered, secreted gp96 (gp69-Ig) induced strong mucosal and systemic immune responses and CD8 expansion that was independent of CD4 help. Immunization of patients with gp96-Ig immunization is especially attractive for induction of mucosal and systemic immunity to SIV/HIV and other diseases. | 2014-02-06 |
| 20140037683 | Methods of Stimulating Protective Immunity Employing Dengue Viral Antigens - Compositions that include at least a portion of at least one pathogen-associated molecular pattern and at least a portion of at least one member selected from the group consisting of a Den1 viral envelope protein, a Den2 viral envelope protein, a Den3 viral envelope protein and a Den4 viral envelope protein are employed in methods to stimulate a protective immune response in a subject. | 2014-02-06 |
| 20140037684 | STABILIZING EXCIPIENT FOR INACTIVATED WHOLE VIRUS VACCINE - The invention relates to a vaccine composition comprising:
| 2014-02-06 |
| 20140037685 | ADJUVANTS THAT ACTIVATE ADAPTIVE IMMUNE SYSTEM BY STIMULATING NLRP3 - A method of identifying an agent, or combination of agents, as a candidate immunological adjuvant is provided comprising contacting a cell comprising a Nod-like receptor (Nlrp3) with the agent. Methods of enhancing immune responses to vaccines are also provided. | 2014-02-06 |
| 20140037686 | LACTOBACILLUS PARACASEI NCC2461 (ST11) FOR USE BY PERINATAL MATERNAL ADMINISTRATION IN THE REDUCTION AND PREVENTION OF ALLERGIES IN PROGENY - The present invention provides a probiotic, | 2014-02-06 |
| 20140037687 | EXOPOLYSACCHARIDE OF SHIGELLA SONNEI BACTERIA, METHOD FOR PRODUCING SAME, VACCINE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME - For the first time, an O-specific polysaccharide antigen that is a | 2014-02-06 |
| 20140037688 | Materials and Methods for Treating Conditions Associated with Pathogenic Biofilm - The subject invention provides materials and methods that effectively support innate immunity and/or disperse pathogenic biofilms using readily available, nontoxic, natural substances, while supporting restoration of normal microbiotic homeostasis. In one embodiment, the subject invention provides anti-biofilm compositions comprising one or more probiotic organisms, anti-microbial honey, and other ingredients such as prebiotic compounds, other hive products, green tea derivatives, other plant derivatives, and vitamin D3. | 2014-02-06 |
| 20140037689 | PHARMACEUTICAL COMPOSITIONS AND METHODS TO VACCINATE AGAINST DISSEMINATED CANDIDIASIS AND OTHER INFECTIOUS AGENTS - The invention provides a vaccine including an isolated Als protein family member having cell adhesion activity, or an immunogenic fragment thereof, with an adjuvant in a pharmaceutically acceptable medium. The invention also provides a method of treating or preventing hematogenously disseminated or mucocutaneous candidiasis. A method of treating or preventing disseminated candidiasis also is provided that includes administering an effective amount of an isolated Als protein family member having cell adhesion activity, or an functional fragment thereof, to inhibit the binding or invasion of | 2014-02-06 |
| 20140037690 | ANTI-ALLERGIC SUBSTANCE, ANTI-ALLERGIC AGENT, AND FOOD - This invention provides an anti-allergic substance that effectively inhibits allergic symptoms by inhibiting production of the IgE antibody associated with the development of allergies. Anti-allergic substances, pharmaceutical products (i.e., anti-allergic agents), and food (i.e., food with health-promoting benefits) containing strawberry-derived glyceraldehyde-3-phosphate do not cause side effects such as those caused by steroids, and such substances can be consumed through daily meals and can alleviate allergic symptoms. | 2014-02-06 |
| 20140037691 | VACCINE COMPOSITION CONTAINING SYNTHETIC ADJUVANT - Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier. | 2014-02-06 |
| 20140037692 | ANTITUMOR VACCINATION USING ALLOGENEIC TUMOR CELLS EXPRESSING ALPHA (1,3)-GALACTOSYLTRANSFERASE - The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through ex vivo gene therapy protocols tumor cells are engineered to express an α(1,3)galactosyl epitope. The cells are then irradiated or otherwise killed and administered to a patient. The α galactosyl epitope causes opsonization of the tumor cell enhancing uptake of the opsonized tumor cell by antigen presenting cells which results in enhanced tumor specific antigen presentation. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal. | 2014-02-06 |
| 20140037693 | 6"-AMINO-6"-DEOXYGALACTOSYLCERAMIDES - This invention relates to galactosylceramide compounds. | 2014-02-06 |
| 20140037694 | ADJUVANT FOR TRANSDERMAL OR TRANSMUCOSAL ADMINISTRATION AND PHARMACEUTICAL PREPARATION CONTAINING SAME - The present invention addresses the problem of providing a low-molecular weight adjuvant which can be administered safely without inducing skin irritation or the like by transdermal or transmucosal administration and is for efficiently enhancing the immunogenicity of an antigen. The present invention relates to an adjuvant for transdermal or transmucosal administration, containing at least one member selected from polyhydric alcohols and derivatives thereof including glycerol, glycerol derivatives and the like. | 2014-02-06 |
| 20140037695 | COMPOSITIONS AND METHODS FOR TARGETING OF TREATING NEOPLASMS - Methods for treating neoplasm, tumors and cancers, using one or more tumor treating drug carriers, haptens and anticancer drugs, alone or in combination with other antineoplastic agents or treatments, are provided. Also provided are compositions, and kits containing the composition for affecting the therapy. | 2014-02-06 |
